Detailed answers about GENETIC DIAGNOSTICS AND THERAPY 21 LTD, including incorporation, status, business activity, and accounts information.
When was GENETIC DIAGNOSTICS AND THERAPY 21 LTD founded?
GENETIC DIAGNOSTICS AND THERAPY 21 LTD was officially incorporated on 22 December 2017 and is registered under company number 11123914. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is GENETIC DIAGNOSTICS AND THERAPY 21 LTD?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of GENETIC DIAGNOSTICS AND THERAPY 21 LTD?
GENETIC DIAGNOSTICS AND THERAPY 21 LTD's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does GENETIC DIAGNOSTICS AND THERAPY 21 LTD do?
GENETIC DIAGNOSTICS AND THERAPY 21 LTD operates in the following sectors: 07290 - Mining of other non-ferrous metal ores, 64304 - Activities of open-ended investment companies. These SIC codes provide insight into the company's business activities and industry focus.
What is GENETIC DIAGNOSTICS AND THERAPY 21 LTD's registered address?
The registered office address of GENETIC DIAGNOSTICS AND THERAPY 21 LTD is 41 DEVONSHIRE STREET, GROUND FLOOR, LONDON, UNITED KINGDOM, W1G 7AJ. This is the official address filed with Companies House for legal and statutory correspondence.
Is GENETIC DIAGNOSTICS AND THERAPY 21 LTD financially stable?
The most recent accounts for GENETIC DIAGNOSTICS AND THERAPY 21 LTD were made up to 31 December 2024, filed as MICRO ENTITY. Next accounts are due by 30 September 2026.